MREO Live signals | Maximize Profits with Getagraph.com

BUY 103808 min ago

@ $3.74

Issued: 14 Feb 2024 @ 12:33

Return: -26.34%

Previous signal: Feb 14 - 11:06

Previous signal: Sell

Return: 0.00 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 15:42):

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally...

Stats
Today's Volume	516 220
Average Volume	1.32M
Market Cap	385.86M
EPS	$0 ( 2024-03-26 )
Next earnings date	( $0 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.77
ATR14	$0.00400 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-08	Ekblom Anders	Buy	45 000	Share Options (Right to buy)
2024-02-08	Ekblom Anders	Buy	19 471	Deferred Restricted Stock Units
2024-02-08	Jacquet Pierre	Buy	45 000	Share Options (Right to buy)
2024-02-08	Jacquet Pierre	Buy	15 553	Deferred Restricted Stock Units
2024-02-08	Yoskowitz Marc J	Buy	45 000	Share Options (Right to buy)

INSIDER POWER
-60.65
Last 97 transactions
Buy: 2 158 393 \| Sell: 9 188 547

Volume Correlation

Long: 0.08 (neutral)

Short: 0.51 (weak)

Signal:(32.376) Neutral

Mereo BioPharma Group plc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mereo BioPharma Group plc Correlation - Currency/Commodity

-0.48
( neutral )

-0.34
( neutral )

0.00
( neutral )

0.05
( neutral )

0.00
( neutral )

0.27
( neutral )

Mereo BioPharma Group plc Financials

Annual	2023
Revenue:	$10.00M
Gross Profit:	$7.43M (74.26 %)
EPS:	$0

FY	2023
Revenue:	$10.00M
Gross Profit:	$7.43M (74.26 %)
EPS:	$0

FY	2022
Revenue:	$1.51M
Gross Profit:	$571 000 (37.89 %)
EPS:	$-0.280

FY	2021
Revenue:	$36.46M
Gross Profit:	$18.56M (50.89 %)
EPS:	$0.159

Financial Reports:

No articles found.

Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.